Computed Tomography-Derived 3D Modeling to Guide Sizing and Planning of Transcatheter Mitral Valve Interventions.

A plethora of catheter-based strategies have been developed to treat mitral valve disease. Evolving 3-dimensional (3D) multidetector computed tomography (MDCT) technology can accurately reconstruct the mitral valve by means of 3-dimensional computational modeling (3DCM) to allow virtual implantation of catheter-based devices. 3D printing complements computational modeling and offers implanting physician teams the opportunity to evaluate devices in life-size replicas of patient-specific cardiac anatomy. MDCT-derived 3D computational and 3D-printed modeling provides unprecedented insights to facilitate hands-on procedural planning, device training, and retrospective procedural evaluation. This overview summarizes current concepts and provides insight into the application of MDCT-derived 3DCM and 3D printing for the planning of transcatheter mitral valve replacement and closure of paravalvular leaks. Additionally, future directions in the development of 3DCM will be discussed.
Competing Interests: Funding Support and Author Disclosures Dr. Wang has served as a consultant for Edwards Lifesciences, Boston Scientific, and Materialise. Dr. Redwood has served as a proctor and consultant for Edwards Lifesciences. Dr. Popma has received institutional grants from Medtronic, Boston Scientific, Edwards Lifesciences, and Abbott; and is a member of the Medical Advisory Board of Edwards Lifesciences. Dr. Little has served as a consultant for Abbot Cardiovascular and Medtronic; and has received a research grant from Siemens Health. Dr. Pfeiffer has served as a consultant for LivaNova Inc.; and has served as a speaker and proctor for Edwards Lifesciences and Abbott Cardiovascular. Dr. Dahle has served as a proctor for Abbot Cardiovascular. Mrs. Minet is a former employee of Materialise NV. Dr. O’Neill has served as a consultant for Boston Scientific. Dr. Van Mieghem has received research grant support from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic; and has served as a consultant for Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, Pie Medical, and Materialise NV. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)